{"doi":"10.1002/9781394207145.ch11","title":"MEK Inhibitors","abstract":null,"journal":"Molecules Engineered Against Oncogenic Proteins and Cancer","year":2023,"id":634961,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"MEK Inhibitors","abstract":"Oncogenic BRAF mutations, key drivers in approximately 50% of cases of cutaneous melanoma, have been successfully targeted by three mutant specific BRAF inhibitors (vemurafenib, dabrafenib and encorafenib) for the treatment of BRAF mutant melanoma. BRAF and MEK inhibitor combinations showed synergistic benefit, sufficient to justify approval for the treatment of metastatic melanoma with BRAF mutations. The three MEK inhibitors, trametinib, binimetinib, and cobimetinib, are included in the combination therapies, while the last approved MEK inhibitor, selumetinib, is prescribed specifically for pediatric patients with neurofibromatosis type 1. This chapter shows several newer MEK inhibitors currently in clinical trials for the treatment of melanoma as well as other solid tumors. The development of BRAF targeting drugs in combination with MEK inhibitors has radically changed clinical practice and outcomes of advanced or metastatic melanoma. The chapter describes the discovery process that led to FDA-approved MEK inhibitors.","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"19910364","pmcid":null,"openalex_id":"https://openalex.org/W4386533979","authors":[],"funders":[],"total_grants":0,"fwci":null,"citation_percentile":null,"influential_citations":0,"citation_trend":[],"oa_status":"gold","license":null,"oa_locations":[{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/9781394207145.ch11","host_type":""},{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/9781394207145.ch11","host_type":""},{"url":"https://onlinelibrary.wiley.com/doi/pdf/10.1002/9781394207145.ch11","host_type":"publisher"},{"url":"http://dx.doi.org/10.1002/9781394207145.ch11","host_type":""}],"fields_of_study":["Melanoma and MAPK Pathways","Synthesis of Tetrazole Derivatives","Beetle Biology and Toxicology Studies"],"mesh_terms":[],"keywords":["Trametinib","Vemurafenib","Dabrafenib","Selumetinib","MEK inhibitor","Melanoma","Medicine","Cancer research","Clinical trial","MAPK/ERK pathway","Oncology","Metastatic melanoma","Pharmacology","Internal medicine","Kinase","Biology"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-06T14:25:47.166990Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}